Results for &quot;&quot;Afatinib&quot;&quot;[mesh_terms]

Diarrhea associated with afatinib: an oral ErbB family blocker.

James Chih-Hsin Yang, Noemi Reguart, Jana Barinoff, Jens Köhler, Martina Uttenreuther-Fischer, Uz Stammberger, Dennis O'Brien, Jürgen Wolf, Ezra E W Cohen

Expert review of anticancer therapy 2014;13(6):729-36

Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption.

Katsuko Kikuchi, Keiko Nozawa, Naoya Yamazaki, Yasuo Nakai, Ayaka Higashiyama, Masayuki Asano, Yutaka Fujiwara, Shintaro Kanda, Yuichiro Ohe, Atsuo Takashima, Narikazu Boku, Akira Inoue, Masanobu Takahashi, Takahiro Mori, Osamu Taguchi, Yasuhiro Inoue, Hitoshi Mizutani

The Journal of dermatology 2019;46(1):18-25

Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN).

J-P Machiels, P Bossi, J Menis, M Lia, C Fortpied, Y Liu, R Lhommel, M Lemort, S Schmitz, S Canevari, L De Cecco, M Guzzo, R Bianchi, P Quattrone, F Crippa, T Duprez, Y Lalami, M Quiriny, N de Saint Aubain, P M Clement, R Coropciuc, E Hauben, L F Licitra

Annals of oncology : official journal of the European Society for Medical Oncology 2019;29(4):985-991

Developing a Mathematical Model of Intracellular Calcium Dynamics for Evaluating Combined Anticancer Effects of Afatinib and RP4010 in Esophageal Cancer.

Yan Chang, Marah Funk, Souvik Roy, Elizabeth Stephenson, Sangyong Choi, Hristo V Kojouharov, Benito Chen, Zui Pan

International journal of molecular sciences 2022;23(3):1763

Epidermal Growth Factor Receptor Mutated Advanced Non-Small Cell Lung Cancer: A Changing Treatment Paradigm.

Suchita Pakkala, Suresh S Ramalingam

Hematology/oncology clinics of North America 2017;31(1):83-99

Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.

Gerald Goh, Ramona Schmid, Kelly Guiver, Wichit Arpornwirat, Imjai Chitapanarux, Vinod Ganju, Seock-Ah Im, Sung-Bae Kim, Arunee Dechaphunkul, Jedzada Maneechavakajorn, Neil Spector, Thomas Yau, Mehdi Afrit, Slim Ben Ahmed, Stephen R Johnston, Neil Gibson, Martina Uttenreuther-Fischer, Javier Herrero, Charles Swanton

PLoS medicine 2017;13(12):e1002136

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.

Yelena Y Janjigian, Egbert F Smit, Harry J M Groen, Leora Horn, Scott Gettinger, D Ross Camidge, Gregory J Riely, Bushi Wang, Yali Fu, Vikram K Chand, Vincent A Miller, William Pao

Cancer discovery 2016;4(9):1036-45

Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.

Hirofumi Mukai, Norikazu Masuda, Hiroshi Ishiguro, Ayako Mitsuma, Takashi Shibata, Jun Yamamura, Masakazu Toi, Aiko Watabe, Akiko Sarashina, Martina Uttenreuther-Fischer, Yuichi Ando

Cancer chemotherapy and pharmacology 2015;76(4):739-50

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.

Jean-Pascal H Machiels, Robert I Haddad, Jérôme Fayette, Lisa F Licitra, Makoto Tahara, Jan B Vermorken, Paul M Clement, Thomas Gauler, Didier Cupissol, Juan José Grau, Joël Guigay, Francesco Caponigro, Gilberto de Castro, Luciano de Souza Viana, Ulrich Keilholz, Joseph M Del Campo, Xiuyu Julie Cong, Eva Ehrnrooth, Ezra E W Cohen

The Lancet. Oncology 2015;16(5):583-94

Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.

James Bean, Gregory J Riely, Marissa Balak, Jenifer L Marks, Marc Ladanyi, Vincent A Miller, William Pao

Clinical cancer research : an official journal of the American Association for Cancer Research 2009;14(22):7519-25

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.

Javier Cortés, Véronique Dieras, Jungsil Ro, Jérôme Barriere, Thomas Bachelot, Sara Hurvitz, Emilie Le Rhun, Marc Espié, Sung-Bae Kim, Andreas Schneeweiss, Joo Hyuk Sohn, Jean-Marc Nabholtz, Pirkko-Liisa Kellokumpu-Lehtinen, Julie Taguchi, Federico Piacentini, Eva Ciruelos, Petri Bono, Mahmoud Ould-Kaci, Flavien Roux, Heikki Joensuu

The Lancet. Oncology 2016;16(16):1700-10